A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Conditions
Heart · Heart Failure With Preserved Ejection Fraction (HFPEF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cardiology and Medicine Clinic, Little Rock, Arkansas, United States
National Institute of Clinical Research, Huntington Beach, California, United States
FOMAT, Santa Maria, California, United States
Invivocure LLC, Van Nuys, California, United States
New Generation of Medical Research, Hialeah, Florida, United States
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
Amavita Health, North Miami Beach, Florida, United States
Broward Research Center, Pembroke Pines, Florida, United States
Eagle Clinical Research, Chicago, Illinois, United States
Chicago Medical Research, Hazel Crest, Illinois, United States
Methodist Medical Center of Illinois, Peoria, Illinois, United States
Louisiana Heart Center, Slidell, Louisiana, United States
Washington University, St Louis, Missouri, United States
Ash Research Clinic, Brick, New Jersey, United States
Erie County Medical Center, Buffalo, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Wake Forest, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
LinQ Research, LLC, Tomball, Texas, United States